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Introduction
Neuropathic pain is deﬁned as pain arising as a direct
consequence of a lesion or disease affecting the somatosensory
system [1]. The most frequent etiologic factors of neuropathic pain
are trauma (including post-surgery scars), metabolic disturbances
(e.g., diabetes mellitus) and ischemia. The pathological mechanism
of neuropathic pain differs signiﬁcantly from that of inﬂammatory
pain; studies have shown that the changes in spinal gene expression
under neuropathy and inﬂammations are different [2]. Thus, the
response to antinociceptive drugs, especially opioids, is not the
same. It has generally been accepted that neuropathic pain is
somewhat resistant to morphine administration in clinical studies
[3,4], and the reduced ability of morphine to attenuate allodynia and
hyperalgesia in experimental models of neuropathic pain has been
demonstrated [5–8]. For these reasons, it is a common clinical
practice to use analgesic drug combinations. The primary approach
to treat neuropathic pain is the use of coanalgesics such as tricyclic
antidepressants (TCA); however, their systemic application is
associated with signiﬁcant side effects, which can hinder the
desired analgesic effect. An alternative approach to this is the topical
administration of analgesics. Currently, the possibility of the topical
Pharmacological Reports 66 (2014) 459–465
A R T I C L E I N F O
Article history:
Received 13 September 2013
Received in revised form 12 November 2013
Accepted 18 November 2013
Available online 3 April 2014
Keywords:
Doxepin
Venlafaxine
Amitriptyline
Neuropathic pain
Morphine
A B S T R A C T
Background: The therapy of neuropathic pain may include the use of co-analgesics, such as
antidepressants, however, their desired analgesic effect is associated with signiﬁcant side effects. An
alternative approach to this is their local administration which has been proposed, but there is little data
regarding their local co-administration with morphine and the nature of the interaction between
morphine and either doxepin or venlafaxine, two antidepressant drugs that have been recently used in
neuropathic pain therapies.
Methods: This study was performed on rats after chronic constriction injury (CCI) to the sciatic nerve.
The von Frey and Hargreaves’ tests were used to assess mechanical allodynia and thermal hyperalgesia,
respectively, after intraplantar (ipl) or subcutaneous (sc) administration of amitriptyline, doxepin, or
venlafaxine, or their ipl co-administration with morphine on day 12–16 after injury.
Results: The ipl administration of amitriptyline (3, 15 mg), doxepin (1, 5, 10, 15 mg), or venlafaxine (2,
7 mg) was effective in antagonizing CCI-induced allodynia. Their sc injection at a site distal to the injured
side, did not induce alterations in pain thresholds, which supports the local mode of action. Of the three
antidepressants used in this study, only ipl co-administration of amitriptyline with morphine
signiﬁcantly enhanced its effect in contrast to doxepin and venlafaxine, both of which weakened the
analgesic effect of morphine.
Conclusions: In summary, the results suggest that when amitriptyline (but not doxepin or venlafaxine) is
locally co-administered with morphine the effectiveness under neuropathic pain is enhanced, although
additional studies are necessary to explain differential mechanisms of interaction of antidepressant
drugs with morphine after local administration.
 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
Abbreviations: CCI, chronic constriction injury; MOR, morphine; AMT, amitripty-
line; DOX, doxepin; VFX, venlafaxine; ipl, intraplantar; sc, subcutaneous.
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use of these drugs that have local analgesic effects has been proposed
[9–14], but there is little data regarding antidepressant topical
coadministration with morphine and the nature of the interaction
between morphine and either doxepin or venlafaxine, two
antidepressant drugs that have been recently used in neuropathic
pain therapies.
Tricyclic antidepressants are the most studied group of
antidepressants for the treatment of neuropathic pain. These drugs
diminish the transmission of nociceptive information from the site
of injury by inhibiting the reuptake of serotonin and norepinephrine
at the synapse, which leads to prolonged activation of the
antinociceptive descending pathways. Interestingly, pain relief
appears to be independent of the primary antidepressant effects
of these drugs. The effects of coadministration of opioids and
antidepressants in different chronic pain models were shown by
some authors. The synergistic action of morphine with amitriptyline
or doxepine in preclinical and clinical study was demonstrated by
some groups [15–18]. Wrzosek et al. [19] has shown that the
combined administration of tramadol with doxepin was more
effective than tramadol and venlafaxine, which provides valuable
information regarding clinical practices and rationalizing the
administration of different drug combinations. It should be noted
that venlafaxine is a structurally novel antidepressant that inhibits
reuptake of 5-hydroxytryptamine and noradrenaline, but unlike
older generation of antidepressants, it has few side effects and has
become increasingly popular in the treatment of pain [20,21].
Considering the possible local analgesic effects of antidepressants,
which may be crucial when they are used in combination with
morphine, we evaluated whether the local use of antidepressants
(amitriptyline, doxepin and venlafaxine) is effective in the chronic
constriction injury model of neuropathic pain in rats and if local
coadministration of these antidepressants with morphine could
inﬂuence its analgesic effect under neuropathic pain conditions.
Materials and methods
Animals
Male Wistar rats (250–350 g) were obtained from Charles River
(Hamburg, Germany) and housed in cages lined with sawdust
under a standard 12/12 h light/dark cycle (lights on at 08:00 h)
with food and water provided ad libitum. All experiments were
performed according to the recommendations of IASP [22] and the
NIH Guide for the Care and Use of Laboratory Animals and were
approved by the local Bioethics Committee (Krako´w, Poland).
Surgical preparations
Chronic constriction injury (CCI) was generated as previously
described by Bennett and Xie [23]. Four ligatures were tied around
the sciatic nerve under sodium pentobarbital anesthesia (60 mg/
kg; ip). The biceps femoris and the gluteus superﬁcial were
separated, and the right sciatic nerve was exposed. The ligatures
(4/0 silk) were tied loosely around the nerve distal to the sciatic
notch at 1 mm distances until they elicited a brief twitch in the
respective hind limb. After surgery, all of the animals (100%)
developed long-lasting neuropathic pain symptoms, including
tactile allodynia and thermal hyperalgesia, which was demon-
strated in our previous papers [6,24–26]. The difference in
response of the ipsilateral paw to von Frey ﬁlaments approxi-
mately 12-16 days after nerve injury in the CCI rats compared to
the control rats was: 0.8 g  0.03 vs. 26 g  0.01, respectively,
whereas the differences in the paw withdrawal test were 5.6 s  0.4
vs. 8 s  0.6, respectively. The behavioral tests were conducted at 12–
16 days after injury when neuropathic pain symptoms, like allodynia
and hyperalgesia have been constant and persistent.
Drug administration
Amitriptyline hydrochloride [3-(10,11-dihydro-5H-diben-
zo[a,d]cyclopenten-5-ylidine) propyldimethyloamine], doxepin
hydrochloride [11-(3-dimethylaminopropylidene)-6,11-dihydro-
dibenz [b,e] oxepine hydrochloride] and venlafaxine hydrochloride
[(+/-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclo-
hexanol hydrochloride] were obtained from Sigma–Aldrich,
(Poznan´, Poland). Morphine hydrochloride was obtained from
Polfa (Kutno, Poland). Drugs were administered to the rats by one
of two methods: (1) intraplantar (ipl) injection of a volume of 20 ml
per each animal to the ipsilateral hind limb sole, or (2)
subcutaneous (sc) injection of a volume of 4 ml/kg body weight
into the skin fold on the neck.
The range of doses was chosen according to our previous
study [19] after ip injection and according to preliminary
experiments with ipl and sc antidepressant administration.
Most of the drugs (amitriptyline hydrochloride, doxepin
hydrochloride and morphine hydrochloride) were dissolved in
the aqua pro injection, but venlafaxine hydrochloride was
dissolved in 12% dimethyl sulfoxide (DMSO). Control animals
were injected ipl with the same volume of the respective vehicle.
The dosages of the drugs for sc injections were calculated
according to the body weight of each animal and were tested in
accordance with the same schedule as described below. After
completion of the experiment, the animals were euthanized by
CO2 asphyxiation.
Behavioral tests
Behavioral tests were conducted on days 12-16 after injury.
Eight animals per an experimental group were used, with each
animal used for one treatment only. In control groups, the number
of animals was higher (up to 16) because the control group was
included in each experiment and the results were pooled. In
behavioral experiments, the control group comprised vehicle-
treated (ipl or sc) CCI animals.
Tactile allodynia (von Frey test)
Allodynia was measured before and 15, 30 and 60 min after ipl
drug administration in the CCI rats. A set of calibrated nylon von
Frey ﬁlaments (Stoelting, Chicago, IL, USA) was used. Animals were
placed in plastic cages with wire net ﬂoor 5 min prior to
experimentation. Increasing ﬁlament strengths were applied
sequentially to the midplantar surface of the hind paw. The
intensity of mechanical stimulation was increased from 0.2 to 26 g
in a graded manner using successive ﬁlaments with greater
pressure until the hind paw was withdrawn as previously
described [6,19,27]. To determine tactile allodynia in rats, the
strength of the von Frey stimuli ranged from 0.5 to 26 g. The
ipsilateral paw was tested in animals in 4 cages twice over 3 min
intervals using von Frey ﬁlaments, and the mean values were
calculated.
Paw withdrawal test–Hargreaves’ test
Thermal hyperalgesia was measured on days 12-16 after
induction of CCI at times before and 20, 45 and 75 min after ipl
drug administration in the CCI rats. The pain threshold to high
temperatures was tested using an Analgesia Meter (Landing, NJ).
CCI rats were placed into 4 individual plastic cages with a glass
ﬂoor 5 min prior to experimentation. A noxious thermal stimulus
was focused through the glass onto the plantar surface of a hind
paw until the animal lifted the paw away [6,28]. The cut-off
latency was 20 s. The ipsilateral paws of the animals in 4 cages
were tested twice over 3 min intervals, and the mean values were
calculated.
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Data analysis
The behavioral data are presented in grams (von Frey test) and
seconds (paw withdrawal test) as the mean  SEM of eight to
sixteen rats per group. Some groups are more numerous because
controls groups were repeated and the data were pooled when there
was no signiﬁcant differences. Inter-group differences were analyzed
by ANOVA Bonferroni’s multiple comparison test (*p < 0.05;
**p < 0.01; ***p < 0.001 compared to vehicle-treated CCI exposed
rats; 8p < 0.05;88p < 0.01;888p < 0.001 compared to morphine-trea-
ted CCI exposed rats; #p < 0.05; ##p < 0.01; ###p < 0.001 compared
to antidepressant-treated CCI exposed rats).
Results
The effect of intraplantar administration of amitriptyline, doxepin and
venlafaxine on mechanical allodynia as measured by the von Frey test
The lowest dose of amitriptyline (0.5 mg) had no signiﬁcant
antiallodynic action. Treatment with amitriptyline at doses of 3
and 15 mg showed a dose-dependent analgesic effect (Fig. 1A) by
reducing allodynia at all the time points measured. This effect
remained signiﬁcant from 15 min until 60 min after administra-
tion of these doses.
The lowest dose of doxepin (1 mg) showed a signiﬁcant
antiallodynic effect measured from 30 min up to 60 min after
administration (Fig. 1B). Treatment with doxepin at a dose of 5
and 10 mg signiﬁcantly reduced allodynia from 30 to 60 min or
15 to 60 min after administration, respectively. Treatment with
venlafaxine at doses of 2 and 7 mg, signiﬁcantly reduced
allodynia at all of the time points measured or only in 15 and
30 min after administration, respectively. The dose of 25 mg had
a signiﬁcant analgesic effect at all time points measured
(Fig. 1C).
The effect of intraplantar co-administration of amitriptyline, doxepin
and venlafaxine with morphine on mechanical allodynia as measured
by the von Frey test
Amitriptyline at a dose of 15 mg exhibited a similar
antiallodynic effect compared to morphine at a dose of 200 mg
as measured by the von Frey test (Fig. 1D). Co-administration of
these two drugs signiﬁcantly potentiated the antiallodynic effect
vs. each drug alone at all time points measured. This effect was
Fig. 1. The effect of amitriptyline (AMT; 0.5, 3, and 15 mg; A), doxepin (DOX; 1, 5, and 10 mg; B) and venlafaxine (VFX; 2, 7, and 25 mg; C) injected to the ipsilateral hind limb
sole (ipl) on mechanical allodynia as measured by von Frey ﬁlaments is presented in the left panel. The effect of ipl co-administration of amitriptyline (AMT; 15 mg; D),
doxepin (DOX; 10 mg; E) or venlafaxine (VFX; 25 mg; F) with morphine (200 mg) injected to the ipsilateral hind limb sole on mechanical allodynia as measured by von Frey
ﬁlaments is presented in the right panel. The experiments were performed on days 12-16 after sciatic nerve ligation. The control group of CCI-subjected rats was treated with
vehicle (V) instead of an antidepressant. The results are presented as the mean  SEM of pressure in grams. Inter-group differences were analyzed by ANOVA Bonferroni’s
multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001 in comparison to vehicle-treated CCI-exposed rats; 8p < 0.05;88p < 0.01;888p < 0.001compared to morphine-treated
CCI-exposed rats; ###p < 0.001 compared to antidepressant-treated CCI-exposed rats.
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statistically signiﬁcant compared to the control group as well as
to the groups treated with either amitriptyline or morphine
alone.
Doxepin at a dose of 10 mg exerted a strong antiallodynic
effect similar to morphine at a dose of 200 mg as measured by the
von Frey test. Co-administration of doxepin with morphine
produced a lower antiallodynic effect than each drug given alone
(Fig. 1E).
Venlafaxine at a dose of 25 mg exerted a stronger antiallodynic
effect compared to morphine at a dose of 200 mg as measured by
the von Frey test. Co-administration of venlafaxine with morphine
elicited a lower antiallodynic effect than each drug given alone
(Fig. 1F).
The effect of intraplantar administration of amitriptyline, doxepin and
venlafaxine on thermal hyperalgesia as measured by the paw
withdrawal test
Amitryptyline at a lower dose of 0.5 mg had no signiﬁcant
antihyperalgesic action. Treatment with amitriptyline at doses of 3
and 15 mg produced a dose-dependent signiﬁcant antihyperalge-
sic effect at 45 (not shown) and 75 min or 20, 45 (not shown) and
75 min after administration, respectively (Fig. 2A).
The doxepin at doses of 1, 5 and 10 mg had no signiﬁcant
hyperalgesic effect. Treatment with doxepin at a dose of 15 mg
signiﬁcantly reduced hyperalgesia at 20 and 45 (not shown) and
75 min after administration (Fig. 2B).
Fig. 2. The effect of amitriptyline (AMT; 0.5, 3, and 15 mg; A), doxepin (DOX; 1, 5, 10, and 15 mg; B) and venlafaxine (VFX; 2, 7, and 25 mg; C) injected to the ipsilateral hind limb
sole (ipl) on thermal hyperalgesia as measured by the paw withdrawal test is presented in the left panel. The effect of ipl co-administration of amitriptyline (AMT; 15 mg; D),
doxepin (DOX; 10 mg; E) or venlafaxine (VFX; 25 mg; F) with morphine (MOR; 200 mg) injected to the ipsilateral hind limb sole on thermal hyperalgesia as measured as the paw
withdrawal test is presented in the right panel. The paw withdrawal test was conducted 20, 45 (not shown) and 75 min after drug administration, on days 12-16 after sciatic nerve
ligation. The control group of CCI-subjected rats was treated with vehicle (V) instead of an antidepressant. The results are presented as the mean  SEM of time in seconds. Inter-
group differences were analyzed by ANOVA Bonferroni’s multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001 in comparison to vehicle-treated CCI-exposed rats.
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Venlafaxine at doses ranging from 2 to 25 mg had no effect on
thermal hyperalgesia at all of the time points measured (Fig. 2C).
The effect of intraplantar co-administration of amitriptyline, doxepin
and venlafaxine with morphine on thermal hyperalgesia as measured
by the paw withdrawal test
Amitriptyline at a dose of 15 mg had a similar antihyperalgesic
effect compared to morphine at a dose of 200 mg as measured by
the paw withdrawal test. Co-administration of amitryptyline with
morphine slightly, nonsigniﬁcantly potentiated antihyperalgesic
effect of each drug given alone (Fig. 2D).
Doxepin at a dose of 10 mg showed a nonsigniﬁcant anti-
hyperalgesic effect. Morphine at a dose of 200 mg caused a
signiﬁcant antihyperalgesic effect only at 75 min after adminis-
tration. However, when the two drugs were co-administered, their
effect was lower than that of each drug given alone at all time
points measured (Fig. 2E).
Venlafaxine at a dose of 25 mg did not cause any signiﬁcant
antihyperalgesic effect at all time points measured. Morphine at a
dose of 200 mg caused a signiﬁcant antihyperalgesic effect only at
75 min after administration. Co-administration of venlafaxine and
morphine produced a similar effect as that observed after each
drug given alone at all time points studied (Fig. 2F).
Comparison of the effects of intraplantar and subcutaneous
administration of amitriptyline, doxepin and venlafaxine on allodynia
and hyperalgesia
Administration of amitriptyline (15 mg) and doxepin (20 mg)
had an antiallodynic and antihyperalgesic effect after ipl adminis-
tration. However, no effect was observed after sc administration of
either of these drugs. The effect of venlafaxine administration
(25 mg) was signiﬁcant in reducing tactile allodynia but not
thermal hyperalgesia and was observed only after ipl administra-
tion (Table 1).
Discussion
Antidepressants are drugs of choice for neuropathic pain
treatment. They have recognized effects in some types of clinical
syndromes. Since the ﬁrst mention of imipramine as an analgesic
in 1960 [29], they have been systematically used for neuropathic
pain syndromes for 40 years [30]. The reduction of morphine effect
in neuropathy after nerve injury could be attributed to the
impairment of opioidergic transmission, e.g. due to a decreased
number of presynaptic opioid receptors caused by loss of neurons
[31–34]. Moreover, during long-term use of morphine its numer-
ous side effects (e.g., respiratory depression, sedation, and
constipation) and tolerance strongly limit its clinical use.
Therefore, lowering of the dose of morphine and its local
administration with a drug which enhances its action would be
beneﬁcial during morphine treatment. Therefore, we investigated
the analgesic effect of amitriptyline and doxepin (tricyclic
antidepressants) as well as venlafaxine (a newer generation drug)
alone and locally coadministered with morphine under neuro-
pathic pain.
Our results show that when applied locally to the ipsilateral
hind limb sole, all three antidepressants attenuated neuropathic
pain symptoms which developed after sciatic nerve injury in rats.
The intraplantar administration of amitriptyline (3, 15 mg),
doxepin (1, 5, 10, 15 mg), or venlafaxine (2, 7 mg) was effective
in antagonizing CCI-induced allodynia. Local mode of action was
checked by a comparison with their subcutaneous injection at a
site distant to the injured one. The antidepressants after sc
administration did not induce alterations in pain thresholds, which
mean that the effect of drugs was not a result of penetration to
other tissues and in consequence was not caused by peripheral
action. Local coadministration of amitriptyline with morphine
signiﬁcantly diminished allodynia and slightly hyperalgesia
comparing with morphine alone. In contrast, coadministration
of either doxepin or venlafaxine with morphine made it less
effective in attenuation of neuropathic pain symptoms. The
analgesic action of antidepressants after local administration
deserves further study due to the ﬁrst and only experimental and
clinical data that focused on the analgesic efﬁcacy of antidepres-
sants after different methods of administration (oral, subcutane-
ous, intraperitoneal, intrathecal, topical) in different models of
pain [9,15,35–38]. The analgesic effect of antidepressants is
different from their action as a mood elevator. Their analgesic
effect may occur soon after their administration, as much lower
doses are needed compared to those used for the treatment of
depression. The plasma concentration level of these drugs that is
necessary to induce an analgesic effect is lower than that in a
psychiatric practice. Investigations on the mechanism of action of
antidepressants in pain treatment were tested in both animal and
human models of acute and chronic pain. It was estimated that
tricyclic antidepressants are effective in the model of neuropathic
pain evoked by ligation of the sciatic nerve in rats [39]. Currently it
is under consideration that antidepressant drugs act not only as
mood elevators but also analgesics in chronic pain syndromes [40].
The antidepressant amitriptyline is used as an adjuvant in the
treatment of a variety of chronic pain conditions. This drug
interacts with many receptors and ion channels, including Na+
channels. Antidepressants may also act by at alpha-adrenergic,
histaminic and cholinergic postsynaptic receptors. These interac-
tions play a role in their analgesic efﬁcacy but are also responsible
for common adverse effects, which can limit their use; thus, either
topical or local administration may create more effective and safer
therapy.
Table 1
Comparison of intraplantar (ipl) and subcutaneous (sc) administration of amitriptyline (AMT, 15 mg), doxepin (DOX, 20 mg) and venlafaxine (VFX; 25 mg) in CCI-subjected
rats. At days 12-16 after sciatic nerve ligation (CCI), antidepressants were administered either by ipl injection to the ipsilateral hind limb sole or by sc injection into the skin
fold on the neck. Tactile allodynia (von Frey test) was measured 30 min after drug administration and thermal hyperalgesia (paw withdrawal test) was measured 45 min after
drug administration. The control group of CCI-subjected rats was treated with vehicle instead of an antidepressant. The results are presented as the mean  SEM of pressure in
grams and latency in seconds. Inter-group differences were analyzed by ANOVA Bonferroni’s multiple comparison test.
von Frey test (g) Paw withdrawal test (s)
CCI model ipl sc ipl sc
Vehicle 0.77  0.06 0.72  0.06 5.61  0.28 5.69  0.48
AMT (15 mg) 11.26  1.90*** 0.74  0.13 11.25  1.06* 6.92  0.55
DOX (20 mg) 15.10  3.63*** 3.58  0.58 20.25  1.06*** 5.21  0.70
VFX (25 mg) 14.81  2.40*** 2.80  0.50 8.75  1.30 2.78  0.48
* p < 0.05 compared to vehicle-treated CCI-exposed rats.
**p < 0.01 compared to vehicle-treated CCI-exposed rats.
*** p < 0.001 compared to vehicle-treated CCI-exposed rats.
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In our study, the dose-dependent action of amitriptyline and
doxepin after local administration was documented. Allodynia
attenuation after treatment with the highest dose of venlafaxine
(25 mg) was also observed. In the paw withdrawal test, the efﬁcacy
at the highest doses of amitriptyline and doxepin as well as a lack
of activity after venlafaxine treatment was observed. Bomholt et al.
[41] showed that in the formalin test, amitriptyline changed the
ratio between different forms of pain behavior, i.e., increased
second phase ﬂinching behavior and reduced second phase licking
behavior. In the chronic constriction injury model of neuropathic
pain, amitriptyline fully reversed thermal hypersensitivity and had
no inﬂuence on mechanical allodynia but signiﬁcantly reduced
mechanical hyperalgesia [41]. These responses are in accordance
with our results, although a full reversal of thermal hyperalgesia in
the paw withdrawal test was not observed. However, the inﬂuence
of intraplantar administration on mechanical allodynia was
important to address. Similarly, in an inﬂammatory model of
pain, amitriptyline treatment reduced pain behavior in the mouse
in the late phase after formalin administration [42], and this action
was stronger than that of venlafaxine.
The effect of doxepin was similar to that of amitriptyline in our
experiments. Its action against allodynia was dose-dependent. In
contrast to both tricyclic antidepressants, venlafaxine did not
reverse thermal hyperalgesia, but attenuation of allodynia was
observed at all of the time points with statistical signiﬁcance
measured only at the highest dose (25 mg). This result is
inconsistent with the results obtained in 2005 by Pedersen et al.
[43] in which venlafaxine was ineffective against mechanical
allodynia in CCI and spinal nerve ligation models. This study also
reported that venlafaxine transiently increased the tail-ﬂick
latency in uninjured animals and attenuated second-phase
ﬂinching in the formalin test in rats [43]. Interestingly, Lang
et al. [21] has shown that venlafaxine administered per os in the CCI
model prevented the development of chronic pain if it was
administered before the constriction to the sciatic nerve and
reversed pain if it was given after, which is in agreement with our
results.
In our investigation, all three antidepressants had an analgesic
effect after topical use. Because there were no publications that
directly compared these drugs, we focused on studies that topically
administered these drugs in neuropathic pain models. Topically
administered doxepin was effective, which is in accordance with the
results from Gerner et al. [44]. The same results were observed after
amitriptyline administration. Our results also conﬁrm the observa-
tions by Sawynok et al., which topically administered amitriptyline
in the formalin model in the rats [45]. Pain-related behavior induced
by local administration of formalin is characterized by the
occurrence of two phases of increased pain sensitivity in rats. In
contrast, in neuropathic pain similar effects are observed only a
short time after injury, but during development of neuropathy the
inﬂammatory component is decreased. Therefore, inﬂammatory
and neuropathic pain use the same mechanisms but differ in their
presentation depending on time after inoculation or injury.
Currently, it is difﬁcult to identify a single ﬁrst choice drug for
neuropathic pain treatment. It appears that coadministration of
two or more drugs provides a better result with a lower risk of
adverse events [46]. In neuropathic pain, the most commonly used
drugs are narcotic analgesics, antidepressants, anticonvulsants,
and some local anesthetics [47,48]. One of the important aspects in
the treatment of neuropathic pain is combination therapy due to
the participation of different mechanisms that may simultaneous-
ly interact with each other [49]. With a suitable combination of
drugs, we are able to use submaximal doses with fewer adverse
effects as well as to obtain more beneﬁts from improved efﬁcacy
[50]. Coadministration of opioids with antidepressants has been
suggested. In this group of drugs, tramadol is interesting because
its mechanism in the central nervous system is similar to that of
antidepressants, i.e., by inhibition of monoamine reuptake from
the synaptic cleft. Antidepressants inhibit the reuptake of
serotonin and norepinephrine from synaptic cleft. These neuro-
modulators by themselves are stimulatory and are also the primary
mediators in the descending antinociceptive pathways. The role of
these neuromodulators is multidimensional, but something to
consider is that activation of serotoninergic and adrenergic
pathways can induce antinociception. Inhibition of monoamine
reuptake evokes pain transmission at the level of the dorsal horn in
the spinal cord. In peripheral neuropathy, blocking alpha-
adrenergic receptors may alleviate pain evoked by adrenergic
stimulation of highly sensitive receptors at injured branched
peripheral nerves [51,52]. The mechanisms of interaction of
antidepressants with the opioid system remain unclear. In 1998,
Gray et al. [53] showed that when acetorphan, an inhibitor of
enzymatic enkephalin degradation, is given before administration
of an antidepressant, the analgesic action of morphine and
antidepressant activities are intensiﬁed. It is considered that in
this case, endogenous peptide release occurs in the region of opioid
receptors after systemic (intraperitoneal) administration of anti-
depressants. There are other investigations that have focused on
the increase of endogenous opioids in the striatum and nucleus
accumbens of rats after chronic administration of antidepressants
[54]. A question regarding the involvement of the opioid system
after local administration of antidepressants still remains unclear.
Initial investigations suggested that tricyclic antidepressants have
a low afﬁnity to opioid receptors [55]. Venlafaxine has been
characterized as being able to act on the opioid system and
enhance opioid analgesia when administered with a selective
opioid agonist, and this action is inhibited by selective opioid
antagonists. [56]. Potentiation of hyperalgesia may be related to
the reported inﬂuence of venlafaxine on kappa opioid receptors
because its effect in mice was blocked by norBNI, a kappa opioid
receptor antagonist [56]. It was documented that in neuropathic
pain, the increased activity of the prodynorphin system is
responsible for the mechanism of allodynia [27]; therefore, the
mechanism of action of venlafaxine may be responsible for the
attenuation of the morphine effect.
Conclusions
Our results suggest that under neuropathic pain in the rat, in
contrast to amitriptyline, which potentiated morphine analgesia,
venlafaxine and doxepin attenuated its effect, although further
studies are necessary to precisely describe the mechanism of this
interaction. Our results suggest that the use of amitriptyline with
morphine may be beneﬁcial due to their interactions. Experimen-
tal characterization of also other antidepressants that could be
proposed for local coadministration with opioid drugs in
neuropathic pain could improve therapy in the future.
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